Indacaterol
Clinical data
Trade namesOnbrez, Arcapta
AHFS/Drugs.comInternational Drug Names
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
Identifiers
  • 5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.218.577 Edit this at Wikidata
Chemical and physical data
FormulaC24H28N2O3
Molar mass392.499 g·mol−1
3D model (JSmol)
  • O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4
  • InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 checkY
  • Key:QZZUEBNBZAPZLX-QFIPXVFZSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist[5] developed by Novartis. It needs to be taken only once a day,[6] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

Medical uses

A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.[7]

History

It was approved by the European Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009,[8] and by the United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011.[9][10] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.[11]

References

  1. ^ "Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011". DailyMed. 1 April 2020. Retrieved 14 June 2021.
  2. ^ "Onbrez Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
  3. ^ "Oslif Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
  4. ^ "Hirobriz Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
  5. ^ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567. S2CID 11930383.
  6. ^ Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007). "Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma". Eur. Respir. J. 29 (5): 871–8. doi:10.1183/09031936.00060006. PMID 17251236.
  7. ^ Geake, James B (2015). "Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease". Reviews. 1 (3): CD010139. doi:10.1002/14651858.CD010139.pub2. PMC 6464646. PMID 25575340.
  8. ^ European Public Assessment Report for Onbrez Breezhaler Archived 2010-01-16 at the Wayback Machine
  9. ^ "FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease" (Press release). U.S. Food and Drug Administration. 2011-07-01. Archived from the original on 2011-07-03. Retrieved 2011-07-02.
  10. ^ "Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383". U.S. Food and Drug Administration. 13 August 2013. Retrieved 14 June 2021.
  11. ^ Faulkner, Sarah (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.
Categories